142 related articles for article (PubMed ID: 34862459)
1. Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML.
Nicosia L; Boffo FL; Ceccacci E; Conforti F; Pallavicini I; Bedin F; Ravasio R; Massignani E; Somervaille TCP; Minucci S; Bonaldi T
Oncogene; 2022 Feb; 41(6):878-894. PubMed ID: 34862459
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
3. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
4. Growth Factor Independence 1B-Mediated Transcriptional Repression and Lineage Allocation Require Lysine-Specific Demethylase 1-Dependent Recruitment of the BHC Complex.
McClellan D; Casey MJ; Bareyan D; Lucente H; Ours C; Velinder M; Singer J; Lone MD; Sun W; Coria Y; Mason CC; Engel ME
Mol Cell Biol; 2019 Jul; 39(13):. PubMed ID: 30988160
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.
Deb G; Wingelhofer B; Amaral FMR; Maiques-Diaz A; Chadwick JA; Spencer GJ; Williams EL; Leong HS; Maes T; Somervaille TCP
Leukemia; 2020 May; 34(5):1266-1277. PubMed ID: 31780813
[TBL] [Abstract][Full Text] [Related]
6. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
Murray-Stewart T; Woster PM; Casero RA
Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
[TBL] [Abstract][Full Text] [Related]
7. A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers.
Sugino N; Kawahara M; Tatsumi G; Kanai A; Matsui H; Yamamoto R; Nagai Y; Fujii S; Shimazu Y; Hishizawa M; Inaba T; Andoh A; Suzuki T; Takaori-Kondo A
Leukemia; 2017 Nov; 31(11):2303-2314. PubMed ID: 28210006
[TBL] [Abstract][Full Text] [Related]
8. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
Barth J; Abou-El-Ardat K; Dalic D; Kurrle N; Maier AM; Mohr S; Schütte J; Vassen L; Greve G; Schulz-Fincke J; Schmitt M; Tosic M; Metzger E; Bug G; Khandanpour C; Wagner SA; Lübbert M; Jung M; Serve H; Schüle R; Berg T
Leukemia; 2019 Jun; 33(6):1411-1426. PubMed ID: 30679800
[TBL] [Abstract][Full Text] [Related]
9. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
[TBL] [Abstract][Full Text] [Related]
10. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.
Cusan M; Cai SF; Mohammad HP; Krivtsov A; Chramiec A; Loizou E; Witkin MD; Smitheman KN; Tenen DG; Ye M; Will B; Steidl U; Kruger RG; Levine RL; Rienhoff HY; Koche RP; Armstrong SA
Blood; 2018 Apr; 131(15):1730-1742. PubMed ID: 29453291
[TBL] [Abstract][Full Text] [Related]
11. The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer.
Wang Y; Zhu Y; Wang Q; Hu H; Li Z; Wang D; Zhang W; Qi B; Ye J; Wu H; Jiang H; Liu L; Yang J; Cheng J
Cancer Lett; 2016 Apr; 374(1):12-21. PubMed ID: 26872725
[TBL] [Abstract][Full Text] [Related]
12. Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date.
Mould DP; McGonagle AE; Wiseman DH; Williams EL; Jordan AM
Med Res Rev; 2015 May; 35(3):586-618. PubMed ID: 25418875
[TBL] [Abstract][Full Text] [Related]
13. Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.
Ravasio R; Ceccacci E; Nicosia L; Hosseini A; Rossi PL; Barozzi I; Fornasari L; Zuffo RD; Valente S; Fioravanti R; Mercurio C; Varasi M; Mattevi A; Mai A; Pavesi G; Bonaldi T; Minucci S
Sci Adv; 2020 Apr; 6(15):eaax2746. PubMed ID: 32284990
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells.
Fang J; Ying H; Mao T; Fang Y; Lu Y; Wang H; Zang I; Wang Z; Lin Y; Zhao M; Luo X; Wang Z; Zhang Y; Zhang C; Xiao W; Wang Y; Tan W; Chen Z; Lu C; Atadja P; Li E; Zhao K; Liu J; Gu J
Oncotarget; 2017 Oct; 8(49):85085-85101. PubMed ID: 29156705
[TBL] [Abstract][Full Text] [Related]
15. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia.
Maiques-Diaz A; Spencer GJ; Lynch JT; Ciceri F; Williams EL; Amaral FMR; Wiseman DH; Harris WJ; Li Y; Sahoo S; Hitchin JR; Mould DP; Fairweather EE; Waszkowycz B; Jordan AM; Smith DL; Somervaille TCP
Cell Rep; 2018 Mar; 22(13):3641-3659. PubMed ID: 29590629
[TBL] [Abstract][Full Text] [Related]
16. LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer.
Li M; Liu M; Han W; Wang Z; Han D; Patalano S; Macoska JA; Balk SP; He HH; Corey E; Gao S; Cai C
Cancer Res; 2023 May; 83(10):1684-1698. PubMed ID: 36877164
[TBL] [Abstract][Full Text] [Related]
17. Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition.
Abdel-Aziz AK; Pallavicini I; Ceccacci E; Meroni G; Saadeldin MK; Varasi M; Minucci S
Haematologica; 2020 Aug; 105(8):2105-2117. PubMed ID: 31537694
[TBL] [Abstract][Full Text] [Related]
18. Natural protoberberine alkaloids, identified as potent selective LSD1 inhibitors, induce AML cell differentiation.
Li ZR; Suo FZ; Guo YJ; Cheng HF; Niu SH; Shen DD; Zhao LJ; Liu ZZ; Maa M; Yu B; Zheng YC; Liu HM
Bioorg Chem; 2020 Apr; 97():103648. PubMed ID: 32065882
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Inhibition of LSD1 for Cancer Treatment.
Yang GJ; Lei PM; Wong SY; Ma DL; Leung CH
Molecules; 2018 Dec; 23(12):. PubMed ID: 30518104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
